PT= Price target (i.e our approximate exit price)Unless stated otherwise, the price next to the ticker is a suitable entry price. An asterisk (*) next to the ticker means one of us owns it. Let us … [Read more...] about Trade-Ideas, Tuesday, Feb. 18th, 2020
Yesterday started out very promising for LJPC. Based on the early trading activity it seemed we would see a sustained breakout to $10+. Instead, the stock ran to a high of $9.38 followed by a gradual … [Read more...] about LJPC Price Action Explained (2/12/20)
Dario Health (NASDAQ: DRIO) Rating: Strong Buy Investment SummaryTicker: DRIO (Last: $8.40)Market Cap: $60MAccumulate: $7-9Price Target: $16-20Timeframe: 0-24 weeks Investment … [Read more...] about Dario Health (Nasdaq: DRIO) is Poised For a Transformative Year in 2020
Rating: BTFD (buy the effin dip) Since our initial coverage, the LJPC thesis has been unfolding according to plan. For a look back at the initial story, click here. With RSI approaching oversold … [Read more...] about LJPC Update
Matinas Biopharma (NYSE: MNTB) Trade Summary Ticker: MTNB (Last: $1.57)Market Cap: $243MAccumulate: $1.50-1.60Price Target: $2.50-3.50Timeframe: 0-12 weeks Trade … [Read more...] about Why Buy MTNB?
(BTFD = Buy The F$%#$ng Dip) NGM is down on low volume attributable to bold short sellers. The stock has not left its channel beginning in November 2019. In our view, shares are being offered … [Read more...] about NGM BTFD!
A few months ago, DelMar Pharmaceuticals (NASDAQ: DMPI) caught our attention as a mischaracterized turn-around story in the making. After digging I found that much of DelMar’s competition have failed … [Read more...] about DelMar Pharmaceuticals (Nasdaq: DMPI) Bull Case is Reinforced by Positive Data Update
Trade Summary Ticker: LJPC (Last 12/26/19: $4.05) Entry: $4.0-5.0 Price Target: $7.96-20 Target Time-frame: 0-8 weeks Trade ThesisAs of 12/25/19, a disconnect remains … [Read more...] about La Jolla Pharmaceuticals (Nasdaq: LJPC) Swing Move
In my last article I summarized my discussions with DelMar Pharmaceuticals’ (Nasdaq: DMPI) President and CEO Saiid Zarrabian and the value proposition DelMar offers investors. To recap, DelMar … [Read more...] about DelMar Pharmaceuticals (Nasdaq: DMPI) Approaches a Key Inflection Point At the 2019 Society for Neuro-Oncology Annual Meeting
Trade Summary Ticker: CCXI (Last: $8.84) Entry: $8.50-8.84 Price Target: $13-15.0+ Target Timeframe: 0-6 weeks Trade ThesisCCXI is an orphan/rare disease-focused company with … [Read more...] about ChemoCentryx Inc Trade Idea